Rabeprazole vs. Esomeprazole

PreclinicalSmall molecule

Rabeprazole vs. Esomeprazole is one of 6 small molecule programs targeting H Pylori Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

H Pylori InfectionUnknown status

H Pylori InfectionPreclinical

Unknown status

Competition

Competitive Landscape

8 competitors in H Pylori Infection

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

5 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

6 3

Levaquin

WWim Janssens

Approved

3 4

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

2 5

Takecab

PPhathom Pharmaceuticals, Inc.

Approved

1 6

Rabeprazole vs. Esomeprazole

NNational Taiwan University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

H Pylori Infection1 trial

The Role of CYP2C19 on the Eradication of H. Pylori Infection:Implication of PK/PD Relationships

Unknown status·NNational Taiwan University Hospital·N/A·NCT00162877·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rabeprazole vs. Esomeprazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rabeprazole vs. Esomeprazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rabeprazole vs. Esomeprazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Taiwan University Hospital

Rabeprazole vs. Esomeprazole

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

H Pylori Infection1 trial

References

Drug Info

Quick Facts

Related News